North Caldwell, NJ, United States of America

Kin-Chun Thomas Luk

USPTO Granted Patents = 31 (Patent Applications = 6)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 8 (Patent Applications = 8)

Average Co-Inventor Count = 3.5

ph-index = 8

Forward Citations = 139(Granted Patents)

Location History:

Essex County, NJ (US) (2003)
N. Caldwell, NJ (US) (2007)
North Caldwell, NJ (US) (1993 - 2014)

Company Filing History:

29 out of 4,942

Hoffmann-la Roche Inc.

Takeda Pharmaceutical Company Limited

patents

where one patent can have more than one assignee

Years Active: 1993-2014

Loading Chart...

31 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 8921383 - Thiazolopyrimidine compounds (2014-12-30),

2. 8673905 - Imidazo pyrazines (2014-03-18),

3. 8658646 - Pyrrolopyrazine kinase inhibitors (2014-02-25),

4. 8362023 - Pyrazolo pyrimidines (2013-01-29),

5. 8044213 - Thiazolyl-benzimidazoles (2011-10-25),

6. 8003785 - Halo-substituted pyrimidodiazepines (2011-08-23),

7. 7994321 - Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives (2011-08-09),

8. 7968554 - Pyrazolo[3,4-d]pyrimidine derivatives (2011-06-28),

9. 7932390 - Substituted thieno[3,2-C]pyridine carboxylic acid derivatives (2011-04-26),

10. 7645764 - Kinase inhibitors and methods for using the same (2010-01-12),

11. 7576082 - Oxindole derivatives (2009-08-18),

12. 7524840 - 7,8-disubstituted pyrazolobenzodiazepines (2009-04-28),

13. 7217717 - Phenalene derivatives (2007-05-15),

14. 7129351 - Pyrimido compounds having antiproliferative activity (2006-10-31),

15. 7115740 - Pyrimido compounds having antiproliferative activity (2006-10-03),

Title: Innovations and Contributions of Kin-Chun Thomas Luk

Introduction

Kin-Chun Thomas Luk, based in North Caldwell, NJ, is an accomplished inventor with a remarkable portfolio of 31 patents. His work primarily focuses on developing novel compounds that hold promise for medical applications, particularly in the realms of auto-immune and inflammatory diseases, as well as treatments for Acute Myeloid Leukemia (AML).

Latest Patents

Among his latest innovations, Luk has developed thiazolopyrimidine compounds, which are noted for their role as SYK inhibitors. These compounds are particularly useful for treating auto-immune and inflammatory diseases. Furthermore, his work with imidazo pyrazines involves the creation of new compounds and their pharmaceutically acceptable salts, aimed at the treatment and amelioration of AML. These advancements reflect his commitment to addressing critical health issues through innovative chemical solutions.

Career Highlights

Kin-Chun Thomas Luk has made significant contributions while working for notable companies in the pharmaceutical sector, including Hoffmann-La Roche Inc. and Roche Palo Alto LLC. His technical expertise and innovative mindset have facilitated the development of novel therapeutic agents, enhancing the capabilities of these organizations in the medical field.

Collaborations

Throughout his career, Luk has collaborated with talented researchers, including Yi Chen and Jin-Jun Liu. These partnerships have fostered a dynamic exchange of ideas and expertise, driving forward the research and development of groundbreaking medical compounds.

Conclusion

Kin-Chun Thomas Luk exemplifies the spirit of innovation that drives progress in the pharmaceutical industry. With a solid foundation of patents and collaborative efforts, he continues to contribute significantly to the field of medicine through his inventive work. His dedication to improving health outcomes through innovative compounds showcases the vital role of inventors in transforming scientific research into practical applications.

This text is generated by artificial intelligence and may not be accurate.